)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
InnoCan Pharma
InnoCan Pharma (INNO) investor relations material
InnoCan Pharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary31 Aug, 2026
Executive summary
Reported revenue of US $5.25 million for Q2 2026, a 25.06% decrease year-over-year.
Gross margin remained strong at 90.8% despite lower sales.
Operating loss increased to US $0.508 million, up 228.3% year-over-year.
Flagship skincare brand VALITIC™ maintained Amazon Best Seller and Amazon's Choice status, reflecting strong consumer demand.
BI Sky subsidiary is expanding sales channels beyond Amazon, including direct-to-consumer and major retail networks.
Financial highlights
Q2 2026 revenue: US $5.25 million, down 25.06% from Q2 2025.
Gross profit: US $4.769 million, down 23.0% year-over-year.
Gross margin: 90.8% in Q2 2026, up from 88.4% in Q2 2025.
Operating loss: US $0.508 million, compared to a smaller loss in Q2 2025.
Cash and cash equivalents: US $6.4 million as of June 30, 2026.
Outlook and guidance
Initiatives underway to diversify sales channels and expand market reach.
Focus on leveraging established brands and customer base for future growth.
Expectation of revenue growth and increased brand visibility over the coming year.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from InnoCan Pharma
- Q1 2026 revenue rose 29.7% sequentially to $6.47M, with gross margin at 91.1%.INNO
Q1 2026 - Q2 2024 revenue up 177% year-over-year, net profit turns positive, driven by BI Sky Global.INNOQ2 2024
- Revenue and profit soared year-over-year, led by new products and robust online sales.INNOQ3 2024
- Revenue more than doubled in 2024, driven by BI Sky Global's strong sales performance.INNOQ4 2024
- Operating profit rebounded in H1 2025 as LPT-CBD platform advanced and Nasdaq listing pursued.INNOQ1 2025
- Operating profit turned positive in H1 2025 amid revenue decline and Nasdaq listing plans.INNOQ2 2025
- 2025 revenues fell 9.6% to US $26.6M, but gross margin stayed high at 89.9%.INNOQ4 2025
- Revenue fell 10% to $21.6M, but gross margin stayed high at 90.2% amid ongoing R&D progress.INNOQ3 2025
Next InnoCan Pharma earnings date
Q3 20261 Dec, 2026
InnoCan Pharma
Next InnoCan Pharma earnings date
Q3 20261 Dec, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)